Saturday 17 October 2026
Export GELS’s income statement to Excel — free account
Gelteq Limited
GELS Healthcare Drug Manufacturers Specialty & Generic
Gelteq Limited’s revenue for fiscal 2025 (year ended June 2025) was $368,500.00, up 282.7% from fiscal 2024.
0.45
0.02
+4.65%
Follow GELS
| Jun '22 | Dec '22 | Jun '23 | Jun '24 | Jun '25 | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 4 |
Altman Z-Score |
— | — | — | — | 0.39 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
2.92 | 2.92 | 2.92 | (1.07) | (2.81) |
Beneish M-Score |
— | — | — | (2.73) | (0.73) |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | (0.38) |
EV/FCF |
0.00 | 0.00 | 0.00 | 0.00 | (0.38) |
Quick Ratio |
0.55 | 0.55 | 0.55 | 0.05 | 0.14 |
Current Ratio |
0.73 | 0.73 | 0.73 | 0.08 | 0.27 |
Net Debt/EBITDA |
(0.67) | (0.67) | (1.11) | (2.20) | (0.91) |
Debt/Assets |
10.99% | 10.99% | 11.01% | 18.52% | 19.64% |
Debt/Equity |
0.13 | 0.13 | 0.13 | 0.25 | 0.27 |
Asset Turnover |
0.00 | 0.03 | 0.03 | 0.01 | 0.03 |
Operating CF/Net income |
0.00 | 0.00 | 0.51 | 0.30 | 0.83 |
Capex/Depreciation |
— | — | (0.06) | (0.12) | (0.53) |
Interest Coverage |
(7.68) | (7.68) | (7.68) | (4.91) | (2.82) |
| 0.00% | 44.10% | (65.48%) | (20.70%) | (42.72%) | |
| 0.00% | (15.59%) | (15.59%) | (16.17%) | (31.28%) | |
ROIC |
(9.35%) | (9.35%) | (9.35%) | (9.73%) | (17.46%) |
Return on Tangible Assets |
938.53% | 938.53% | 938.53% | 100.00% | 161.70% |
Average Days of Receivables |
203.08 | 203.08 | 203.08 | 454.83 | 294.87 |
Research and Development Expense of Revenue |
107.25% | 107.25% | 107.18% | 187.95% | 110.47% |
Selling, General and Administrative Expense of Revenue |
287.22% | 287.22% | 26.91% | 12.36% | 35.88% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.96 | 0.98 | 0.92 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
0.00 | 0.00 | 0.05 | 0.01 | 0.04 |
Operating CF per Share |
— | — | (0.15) | (0.09) | (0.39) |
Capex per Share |
— | — | (0.01) | (0.01) | (0.04) |
Free Cash Flow per Share |
— | — | (0.16) | (0.10) | (0.43) |
Cash per Share |
0.00 | 0.00 | 0.03 | 0.00 | 0.02 |
Shareholders Equity per Share |
0.00 | 0.00 | 1.58 | 1.22 | 1.10 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 0.00 | 1.58 | 1.22 | 1.10 |
Free Cash Flow |
— | — | (1.24) | (0.80) | (3.99) |
Working Capital |
(0.25) | (0.25) | (0.25) | (2.34) | (2.67) |
Capital Expenditures |
— | — | (0.05) | (0.10) | (0.42) |
Net Current Asset Value |
(1.92) | (1.92) | (1.92) | (3.50) | (2.70) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.12 | 1.01 | 1.13 |
| Other line items | |||||
Depreciation/Fixed assets |
— | — | 0.00 | 72.92 | 76.89 |
Cash ROIC |
0.00% | 0.00% | (8.57%) | (6.42%) | (30.26%) |
Accounts Receivable Turnover |
0.00 | 1.80 | 1.80 | 0.55 | 1.76 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.11 |
Inventory Turnover |
0.00 | 0.51 | 0.51 | — | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 8,845.43 | 0.00 | 1,810.34 |
Days of Inventory on Hand |
711.14 | 711.14 | 711.14 | — | 0.00 |
Average Receivables |
— | 0.23 | 0.23 | 0.18 | 0.21 |
Average Payables |
— | — | — | 0.91 | 0.70 |
Average Inventory |
— | 0.06 | 0.06 | — | — |
Average Assets |
— | 15.14 | 15.14 | 14.38 | 13.76 |
Average Common Equity |
— | (5.35) | 3.60 | 11.24 | 10.07 |
Columns are period end dates · fundamentals updated 5 Oct 2026